The effect of IDH inhibitors in AML patients.

Project Summary Title and Description

The effect of IDH inhibitors in AML patients.
12% of patients with AML harbor mutation at Isocitrate dehydrogenase enzyme (IDH).Mutations at these enzymes result in high level of R2 hydroxyglutarate which competes with 2-alpha-hydroxygluterate resulted in DNA and histone hypermethylation. DNA and histone hypermethylation inhibits cell differentiation and promotes leukemic transformation. Ivosidenib and Enasidenib are IDH inhibitors that promotes cell differentiation and showed promising activity in phase1 and 2 trials in relapse/refractory AML patients and in elderly patients who are not candidate for traditional induction regimens. In this systematic review and meta-analysis, we intend to integrate the results of phase1 and 2 trials that looked at the efficacy and the side effects of IDH inhibitor. Therefore,we will have a clearer picture regarding the efficacy and side effect of these medications.
Authors of Report
Methodology description
We will use the ("Metaprop") package in R in order to integrate the results pertaining to the Objective response, Complete remission, and other response outcomes in addition to grade 3 and 4 Treatment Emergent Adverse Events (TEAE) in these trials.
Notes The data was entered using the SRDR built-in data abstraction functions and templates prospectively from each included study.
Funding Source

Key Questions

1. What are the Objective response rates (ORR), Complete remission rates (CR) among AML patients who had received IDH inhibitors.
2. What are the main treatment emergent adverse events that are associated with IDH inhibitors.

Associated Extraction Forms

Downloadable Data Content

  • XLSX Project Data